To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

ID#: NCT04551053

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: Phase 3

Recruitment Status: Recruiting

Start Date: May 26, 2021

End Date: December 31, 2023

Contact Information:
Incyte Corporation Call Center (US)
1.855.463.3463
Incyte Corporation Call Center (ex-US)
+800 00027423
Summary: The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.
Eligibility:

Inclusion Criteria:

- Diagnosis of PMF, PPV-MF, or PET-MF.

- DIPSS risk category of intermediate-1, intermediate-2, or high.

- Treated with ruxolitinib for ≥ 3 months with a stable dose for at least the last 8 weeks prior to Day 1

- Palpable spleen of ≥ 5 cm below the left costal margin on physical examination at the screening visit.

- Active symptoms of MF at the screening visit, as demonstrated by the presence of a TSS of ≥ 10 using the Screening Symptom Form.

- Participants with an ECOG performance status score of 0, 1, or 2.

- Screening bone marrow biopsy specimen and pathology report(s) available that was obtained within the prior 2 months or willingness to undergo a bone marrow biopsy at screening/baseline; willingness to undergo bone marrow biopsy at Week 24 and every 24 weeks there after. Screening/baseline biopsy specimen must show diagnosis of MF.

- Life expectancy of at least 24 weeks.

- Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

- Prior therapy with any drug that inhibits PI3K (examples of drugs targeting this pathway include but are not limited to INCB040093, idelalisib, duvelisib, buparlisib, copanlisib, and umbralisib).

- Use of experimental drug therapy for MF or any other standard drug used for MF (whether for treatment of MF or another indication) with the exception of ruxolitinib, within 3 months of starting study drug, and/or lack of recovery from all toxicities from previous therapy (except ruxolitinib) to Grade 1 or better.

- Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications.

- Recent history of inadequate bone marrow reserve.

- Inadequate liver and renal function at screening.

- Active bacterial, fungal, parasitic, or viral infection that requires therapy.

- Active HBV or HCV infection that requires treatment or at risk for HBV reactivation.

- Known HIV infection.

- Uncontrolled, severe, or unstable cardiac disease that in the investigator's opinion may jeopardize the safety of the participant or compliance with the Protocol.

- Active invasive malignancy over the previous 2 years.

- Splenic irradiation within 6 months before receiving the first dose of study drug.

- Concurrent use of any prohibited medications.

- Active alcohol or drug addiction that would interfere with the ability to comply with the study requirements.

- Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half lives(whichever is longer) before the first dose of study drug or anticipated during the study.

- Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.

- Currently breastfeeding or pregnant.

- Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

- History of Grade 3 or 4 irAEs from prior immunotherapy.

- Receipt of any live vaccine within 30 days of the first dose of study drug

- Unwillingness to receive RBC transfusions to treat low hemoglobin levels.

- Known hypersensitivity or severe reaction to parsaclisib or ruxolitinib or excipients of parsaclisib/matching placebo or ruxolitinib formulations.